Background:The STOP-CoV study is an ongoing longitudinal decentralized cohort study assessing the safety and efficacy of the SARS-CoV-2 vaccine. There are limited longitudinal reports on the use of self-collected dried blood spots (DBS) in the elderly population to assess COVID immunity. Objective: To evaluate the feasibility and acceptability of self-collected dried blood spots (DBS) and assess participant characteristics associated with completion rates and specimen adequacy. Methods: 1286 ambulatory adults, including 911 older (70+ years old) and 375 younger (30-50 years) were recruited in Ontario, Canada, between May and July 2021. DBS were requested every three months after the initial vaccine series and 3-4 weeks after vaccine boosters. Results: Of the participants, 2 did not meet screening criteria and 79 consenting participants did not complete any study activities. Among the remaining 1205, 94.3% submitted at least one DBS, and 68.4% submitted all expected specimens. 98.1% of specimens were submitted within the expected time window, and 93.9% were adequate for serology testing across the study. Higher DBS adequacy rates were observed for females compared to males (OR: 1.60; 95% CI: 1.04-2.47) after adjusting for time, age cohort, race, and level of education. The proportion of specimens that were adequate for testing increased over time. Conclusion: Using self-collected DBS for SARS-CoV-2 vaccine response assessment in the elderly ambulatory community is feasible, acceptable, and resulted in high submission rates, specimen adequacy, and retention over 48 weeks. Remote self-collection of DBS can increase recruitment, engagement, and retention of underrepresented and/or vulnerable communities in research.